Certara, Inc. CERT
11.73 USD -0.39 (-3.26%)
At closeNov 11, 2026, 4:00 PM EST
11.73 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
11.67 Day range 12.38
4.48 52-week range 12.22
- YTD
- +33.14%
- 1 year
- +36.71%
News
seekingalpha.com Certara, Inc. (CERT) Q3 2026 Earnings Call Transcript Certara, Inc. ( CERT ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Jon Resnick - CEO & Director Faiz Mohammed - Interim CFO, Senior VP of Finance, Treasurer and Principal…
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $12 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $9 to $12.
marketbeat.com Certara Q3 Earnings Call Highlights Certara NASDAQ: CERT reported 4% revenue growth in the third quarter of 2026 as double-digit software growth offset a decline in services, while cost reductions and a favorable sales mix helped lift…
zacks.com Certara, Inc. (CERT) Tops Q3 Earnings and Revenue Estimates Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.14 per share a year ago.
benzinga.com Certara Q3 2026 Earnings Call Transcript Certara (NASDAQ:CERT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Certara Narrows FY2026 Adj EPS Guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 Est; Revenue for 2026 FY is expected to be up by 2% to 3% YoY Certara (NASDAQ:CERT) narrows FY2026 Adj EPS guidance from $0.31-$0.36 to $0.31-$0.34 vs $0.34 analyst estimate. Revenue for 2026 FY is expected to be up by 2% to 3% YoY
globenewswire.com Certara Reports Third Quarter 2026 Financial Results Certara delivers a solid quarter with double-digit software revenue growth Updates 2026 financial outlook Appoints Grant Peterson Chief Product Officer Company to host conference call and webcast…
globenewswire.com Birchtech Files Brief in Federal Circuit Supporting the $78 Million Patent Infringement Judgment Against CERT Defendants Brief Details the Evidence and Law Supporting the Jury's Findings on Inducement, Contributory Infringement and Damages; Post-Judgment Interest Continues to Accrue During the Appeal CORSICANA, Texas,…
globenewswire.com Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026 RADNOR, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third…
defenseworld.net Weave Communications (NYSE:WEAV) versus Certara (NASDAQ:CERT) Head-To-Head Comparison Certara (NASDAQ: CERT - Get Free Report) and Weave Communications (NYSE: WEAV - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the…
benzinga.com Keybanc Maintains Overweight on Certara, Raises Price Target to $12 Keybanc analyst Scott Schoenhaus maintains Certara (NASDAQ:CERT) with a Overweight and raises the price target from $9 to $12.
benzinga.com TD Cowen Maintains Buy on Certara, Raises Price Target to $11 TD Cowen analyst Brendan Smith maintains Certara (NASDAQ:CERT) with a Buy and raises the price target from $9 to $11.
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $9 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $7.5 to $9.
benzinga.com UBS Downgrades Certara to Neutral, Maintains Price Target to $10 UBS analyst Kevin Caliendo downgrades Certara (NASDAQ:CERT) from Buy to Neutral and maintains the price target from $10 to $10.
defenseworld.net Critical Contrast: Certara (NASDAQ:CERT) versus Doximity (NYSE:DOCS) Certara (NASDAQ: CERT - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the…
defenseworld.net OneMedNet (NASDAQ:ONMD) and Certara (NASDAQ:CERT) Financial Comparison Certara (NASDAQ: CERT - Get Free Report) and OneMedNet (NASDAQ: ONMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies…
defenseworld.net Bank of New York Mellon Corp Purchases Shares of 731,012 Certara, Inc. $CERT Bank of New York Mellon Corp purchased a new position in Certara, Inc. (NASDAQ: CERT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
globenewswire.com The Market Just Told You Which Layer Of AI Biology It Is Paying For AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the…
defenseworld.net Definitive Healthcare (NASDAQ:DH) & Certara (NASDAQ:CERT) Financial Comparison Definitive Healthcare (NASDAQ: DH - Get Free Report) and Certara (NASDAQ: CERT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the…
defenseworld.net BlackRock Inc. Acquires New Stake in Certara, Inc. $CERT BlackRock Inc. purchased a new position in shares of Certara, Inc. (NASDAQ: CERT) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange…
seekingalpha.com Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript Cerrado Gold Inc. (CERT:CA) Q2 2026 Earnings Call Transcript
benzinga.com Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $6.5 to $7.5.
seekingalpha.com Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
marketbeat.com Certara Q2 Earnings Call Highlights Certara NASDAQ: CERT reported second-quarter 2026 revenue of $93.3 million, up 1% year over year, as software growth offset a decline in services revenue. Management reaffirmed its full-year revenue…
zacks.com Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates Certara, Inc. (CERT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.07 per share a year ago.
benzinga.com Transcript: Certara Q2 2026 Earnings Conference Call Certara (NASDAQ:CERT) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by Benzinga…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
benzinga.com Certara Lowers FY2026 Adj EPS Guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 Est; Lowers FY2026 Sales Guidance from $395.000M-$405.000M to $367.000M-$382.000M vs $398.585M Est Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.35-$0.41 to $0.31-$0.36 vs $0.38 analyst estimate. Lowers FY2026 sales outlook from $395.000 million-$405.000 million to $367.000…- benzinga.com Certara Q2 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $93.271M Miss $98.392M Estimate Certara (NASDAQ:CERT) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year. The…
globenewswire.com Certara Reports Second Quarter 2026 Financial Results Appoints Julien Perrier Chief Commercial Officer Completes previously authorized $100 million share repurchase program; Board authorizes additional $50 million under repurchase program Reaffirms 2026…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Certara, Inc. ("Certara" or the "Company") (NASDAQ: CERT). Such investors are advised to…
prnewswire.com An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers /PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
benzinga.com Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & More Apple partners with Broadcom on a multiyear agreement exceeding $30 billion to develop custom silicon and advanced connectivity technologies in America.
benzinga.com Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives Nvidia expands its life sciences AI ecosystem through a Certara partnership and QwikAgents' entry into its developer program.- benzinga.com Certara Partners With NVIDIA To Advance Its Open Integrated AI Platform, Unifying Scientific Software, Regulatory Expertise, And Proprietary Datasets With AI-First, Agentic Frameworks Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, is partnering with NVIDIA to advance Certara's open integrated AI platform, unifying its scientific software,…
benzinga.com Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session US stock futures mixed, Franklin Covey Co drops 19.7% after lowering revenue guidance. Other stocks moving lower in pre-market trading.- benzinga.com Craig-Hallum Maintains Hold on Certara, Lowers Price Target to $8 Craig-Hallum analyst Matthew Hewitt maintains Certara (NASDAQ:CERT) with a Hold and lowers the price target from $10 to $8.
- benzinga.com BMO Capital Maintains Market Perform on Certara, Lowers Price Target to $6 BMO Capital analyst Sean Dodge maintains Certara (NASDAQ:CERT) with a Market Perform and lowers the price target from $7 to $6.
- benzinga.com Barclays Maintains Equal-Weight on Certara, Lowers Price Target to $6.5 Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $8 to $6.5.
- benzinga.com Stephens & Co. Maintains Overweight on Certara, Lowers Price Target to $9 Stephens & Co. analyst Jeff Garro maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $10 to $9.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Certara, Lowers Price Target to $10 Morgan Stanley analyst Sean Laaman maintains Certara (NASDAQ:CERT) with a Equal-Weight and lowers the price target from $11 to $10.
- benzinga.com Baird Maintains Neutral on Certara, Lowers Price Target to $6 Baird analyst Joe Vruwink maintains Certara (NASDAQ:CERT) with a Neutral and lowers the price target from $7 to $6.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com S&P 500 Tops 7,400 As Copper Hits Record Highs: Stock Market Today Small caps lead a mixed Wall Street session as Trump rejects Iran's peace response, sending crude back above $97, copper to a record and silver up 7%.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Certara Lowers FY2026 Adj EPS Guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 Est; Lowers FY2026 Sales Guidance from $418.800M-$435.552M to $395.000M-$405.000M vs $425.854M Est Certara (NASDAQ:CERT) lowers FY2026 Adj EPS guidance from $0.44-$0.48 to $0.35-$0.41 vs $0.45 analyst estimate. Lowers FY2026 sales outlook from $418.800 million-$435.552 million to $395.000…
benzinga.com Certara Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $106.900M Beat $106.095M Estimate Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 35.71 percent decrease over earnings of $0.14 per…- benzinga.com Altasciences And Certara Announce Strategic Partnership To Accelerate Early-Phase Development Programs Altasciences, a fully integrated drug development solution company, andCertara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to…
benzinga.com Certara Strategic Business Divestiture Comes At Right Time, Says Analyst Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.